NEW YORK, Dec. 6, 2017 /PRNewswire/ -- In keeping with the commitment to dynamically provide members with timely information, WallStEquities.com has issued free tailored Stock Review on TMO, A, IQV, and CRL which is a click away at www.wallstequities.com/registration. Ahead of today's trading session, WallStEquities.com monitors Thermo Fisher Scientific Inc. (NYSE: TMO), Agilent Technologies Inc. (NYSE: A), IQVIA Holdings Inc. (NYSE: IQV), and Charles River Laboratories International Inc. (NYSE: CRL). Companies in the Medical Laboratories and Research space focus on performing various tests on patients that give them information on patients' health. These firms, as a whole, tend to offer higher dividend yields than the wider Healthcare sector. Wall St. Equities has a wide array of free research reports which include today's stock picks, register now to access them at:
Thermo Fisher Scientific
On Tuesday, shares in Waltham, Massachusetts headquartered Thermo Fisher Scientific Inc. recorded a trading volume of 2.23 million shares, which was above their three months average volume of 1.49 million shares. The stock ended at $182.45, climbing 0.23% from the last trading session. The Company's shares have gained 29.31% on an YTD basis. The stock is trading above its 200-day moving average by 3.65%. Furthermore, shares of the Company, which provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide, have a Relative Strength Index (RSI) of 32.85.
On November 09th, 2017, Thermo Fisher Scientific announced that its Board of Directors declared a quarterly cash dividend of $0.15 per share. The dividend will be paid on January 15th, 2018, to shareholders of record as of December 15th, 2017. Follow the link below to your free research report on TMO at:
Santa Clara, California headquartered Agilent Technologies Inc.'s stock finished yesterday's session 0.62% lower at $65.83. A total volume of 2.38 million shares was traded, which was above their three months average volume of 1.65 million shares. The Company's shares have gained 1.73% over the previous three months and 44.49% on an YTD basis. The stock is trading above its 200-day moving average by 9.05%. Furthermore, shares of Agilent Technologies, which provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide, have an RSI of 37.86.
On November 15th, 2017, Agilent Technologies announced that its board of directors has increased the Company's quarterly dividend to 14.9 cents per share of common stock. The dividend will be paid on January 24th, 2018, to all shareholders of record as of the close of business on January 02nd, 2018.
On November 21st, 2017, research firm Barclays reiterated its 'Overweight' rating on the Company's stock with an increase of the target price from $67 a share to $71 a share. The free technical report on A can be accessed at:
At the close of trading on Tuesday, shares in Durham, North Carolina headquartered IQVIA Holdings Inc. saw a slight correction of 0.27%, ending the day at $101.00. The stock recorded a trading volume of 1.01 million shares. The Company's shares have advanced 4.94% in the previous three months and 32.81% since the start of this year. The stock is trading 11.94% above its 200-day moving average. Moreover, shares of IQVIA, which provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and Asia/Pacific, have an RSI of 42.34. Sign up for free on Wall St. Equities and claim the latest report on IQV at:
Charles River Labs International
Wilmington, Massachusetts headquartered Charles River Laboratories International Inc.'s shares ended the day 0.24% lower at $101.82. A total volume of 443,446 shares was traded, which was above their three months average volume of 403,530 shares. The stock has gained 33.64% on an YTD basis. The Company's shares are trading 2.95% above their 200-day moving average. Additionally, shares of the Company, which provides drug discovery and development services worldwide, have an RSI of 36.88.
On November 09th, 2017, Charles River Labs reported its results for Q3. Revenue from continuing operations was $464.2 million for Q3 2017, GAAP net income from continuing operations was $52.5 million, and diluted earnings per share on a GAAP basis were $1.09. During the quarter, the Company repurchased 350,000 shares, for a total of $36.0 million. As of September 30th, 2017, it had $129.1 million available on its authorized stock repurchase program. See the free research coverage on CRL at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Wall St. Equities